Navigation Links
Microbix Has Best-Ever Quarterly Sales
Date:10/20/2010

ially from those set forth in the forward-looking statements including the risks associated with failure to get regulatory approval, and release, of Kinlytic for distribution in Canada, the US and other regions of the world;; risks inherent in moving onto new markets or developing and launching new products or engaging new partners; risks associated with commercializing the technologies including sales may not reach sales targets or be made at all, there is no guarantee that the Company will complete development of any technology and if it does that it will perform to commercially exploitable levels, other technologies may emerge before any technology developed by the Company enters the market, royalty rates may not be achievable, markets may not sustain demand for any product should world economies shift significantly, market utilization rates may not be reached, market value of products may vary, product launch dates and market utilization timetables may not be met; risks associated with failure to develop and commercialize LumiSort; non-adoption of LumiSort; competition in Microbix' core business; general economic conditions; intellectual property risks including challenges to protecting the Company's intellectual property rights, patents may not provide adequate protection of the Company's intellectual property, may not be successfully prosecuted and may be subject to challenge and risks of infringement of third party rights; risks associated with financing the China joint venture, that includes obtaining all funds needed to launch or complete the project; risks affecting timely and cost effective construction and operation of the Microbix-Hunan facility; risks associated with operating in foreign jurisdictions, including operating in China with its evolving legal and economic infrastructure and the involvement of the Chinese government departments at national, state and local levels in business and economic matters; creating risks associated with various levels
'/>"/>
SOURCE Microbix Biosystems Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Microbix Uses Core Business Cashflow To Fund Late-Stage Pipeline To Build Shareholder Value In 2009
2. Microbix First Quarter Sales Grow Over 50% With Continued Progress On The Pipeline
3. Microbix Announces A New Technology Platform For The SST Project
4. Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half 09
5. Microbix Files First Patent Applications On Novel Technology Platform For Large Semen Sexing Market
6. Microbix Sales Grow 22% For Nine Months
7. Microbix Pipeline Set To Reach Milestones In 2010
8. Microbix And Hunan Biopharmaceutical To Build Asias Largest Influenza Vaccine Facility
9. Microbix Biosystems Provides a Corporate Update
10. Microbix Biosystems Re-files Annual Results With OSC
11. Microbix Signs Marketing Agreement For Kinlytic(R)(Urokinase) In Growing Middle East Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)...  Researchers have pioneered a revolutionary new way ... called Virtual Finger, allows scientists to move through ... synapses using the flat surface of their computer ... studies orders of magnitude more efficient, saving time, ... many areas of experimental biology. The software and ...
(Date:7/10/2014)... Ohio (PRWEB) July 10, 2014 Understanding ... ion channel-expressing cell lines, and the gap that currently ... cells that expand its industry-leading portfolio of validated ion ... on ion channel-expressing cell lines, as ion channels control ... to control this activity creates the potential to treat ...
(Date:7/10/2014)... QC (PRWEB) July 10, 2014 EvoDerma ... and convenience. This rejuvenating device now comes with a second ... develops over time. , The new cup is thinner on ... design works to target rough, thin and uneven surfaces on ... firm cup for a stimulating treatment on areas such as ...
(Date:7/10/2014)... 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, the ... announced an agreement with Lineagen, Inc., to ... NextStep Dx PLUS.  Lineagen, focused on ... disorders, currently offers FirstStep Dx PLUS, ... used by healthcare providers as a first-line ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... the future will utilise technologies not currently available. An ... carbon nanotubes as interconnects for computer chips. This is ... work from nanotechnology researchers within the Materials Ireland Polymer ... work to develop such junction structure nanotubes used various ...
... DIEGO, Nov. 21 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ... 19th Annual,Piper Jaffray Healthcare Conference on Tuesday, November 27, ... is being held at the Pierre Hotel,in New York., ... of Anadys,Pharmaceuticals, Inc., will present an overview of Anadys ...
... SOUTH SAN FRANCISCO, Calif., Nov. 21 ,Exelixis, Inc. (Nasdaq: ... the company,s president and chief executive officer will present ... 1:00 p.m.,ET / 10:00 a.m. PT on Wednesday, November ... may be accessed in the Event,Calendar page under Investors ...
Cached Biology Technology:Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference 2
(Date:7/11/2014)... "mouse TRAP" to capture the early signs of kidney ... the Journal of Clinical Investigation . Their new ... extract cellular and genetic information from a variety of ... Institute for Medical Research in 2008, TRAP involves attaching ... of the cell type of interest. Scientists can then ...
(Date:7/11/2014)... Researchers from Salk Institute for Biological Studies, BGI, ... the safety and reliability of the existing targeted ... method, TALEN-HDAdV, which could significantly increased gene-correction efficiency ... study published online in Cell Stell Cell ... cell-based gene therapy. , The combination of stem ...
(Date:7/11/2014)... two different ways that allow unprecedented experimental insights ... of oxygen molecules in photosynthesis. The two studies ... Nature Communications . , "The new knowledge will ... oxidation, which are key components for building artificial ... energy in fuels like hydrogen, ethanol or methanol," ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Molecular snapshots of oxygen formation in photosynthesis 2
... Mass., Sept. 4, 2008 Declaring the success of ... philanthropists Eli and Edythe Broad announced today that they ... of Harvard and MIT to $600 million. Adding to ... gave an endowment of $400 million to convert the ...
... and New South Wales have put aside their competitive ... project, as announced by Innovation Minister Gavin Jennings and ... today. Scientists from the Monash Institute of ... will compare two different methods of creating patient-specific stem ...
... University of Texas Medical Branch at Galveston researchers have discovered ... Ebola Zaire virus infects cells a critical step to ... the virus. Ebola produces severe and often fatal hemorrhagic ... 90 percent in some outbreaks. No vaccine or antiviral therapy ...
Cached Biology News:Eli and Edythe L. Broad make unprecedented gift to endow Broad Institute of Harvard & MIT 2Eli and Edythe L. Broad make unprecedented gift to endow Broad Institute of Harvard & MIT 3Eli and Edythe L. Broad make unprecedented gift to endow Broad Institute of Harvard & MIT 4Eli and Edythe L. Broad make unprecedented gift to endow Broad Institute of Harvard & MIT 5Stem cell research puts interstate rivalry on hold 2Scientists uncover Ebola cell-invasion strategy 2
... of Taq DNA polymerase. It is a ... Expressed from a gene construct in E. ... 5'-3' exonuclease domain of the DNA polymerase-encoding ... and even more heat-stable DNA polymerase activity ...
... (ELISA) test kits are qualitative one-step kits ... of drugs and/or their metabolites in forensic ... use only. It is recommended that all ... method such as GC/MS. The simple ...
... inhibitor that noncovalently binds and inactivates neutral pancreatic ... RNase 1, T1, T2, H, U1, U2 or ... inhibitor in that it has a more robust ... RNase in the absence of DTT or other ...
...
Biology Products: